CoChat

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Open access
Ho, Winson S., Wang, Herui, Maggio, Dominic, Kovach, John S., Zhang, Qi, Song, Qi, Marincola, Francesco M., Heiss, John D., Gilbert, Mark R., Lu, Rongze, Zhuang, Zhengping · 2018 · Nature Communications
Cited by 93

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Mounting evidence suggests that inhibition of protein phosphatase-2A (PP2A), a serine/threonine phosphatase, could enhance anticancer immunity. However, drugs targeting PP2A are not currently available. Here, we report that a PP2A inhibitor, LB-100, when combined with anti-PD-1 (aPD-1) blockade can synergistically elicit a durable immune-mediated antitumor response in a murine CT26 colon cancer model. This effect is T-cell dependent, leading to regression of a significant proportion of tumors. Analysis of tumor lymphocytes demonstrates enhanced effector T-cell and reduced suppressive regulatory T-cell infiltration. Clearance of tumor establishes antigen-specific secondary protective immunity. A synergistic effect of LB-100 and aPD-1 blockade is also observed in B16 melanoma model. In addition, LB-100 activates the mTORC1 signaling pathway resulting in decreased differentiation of naive CD4 cells into regulatory T cells. There is also increased expression of Th1 and decreased expression of Th2 cytokines. These data highlight the translational potential of PP2A inhibition in combination with checkpoint inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04425-z

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 33

  1. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015). · DOI · Paper page
  2. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010). · DOI · Paper page
  3. Taffs, R. E., Redegeld, F. A. & Sitkovsky, M. V. Modulation of cytolytic T lymphocyte functions by an inhibitor of serine/threonine phosphatase, okadaic acid. Enhancement of cytolytic T lymphocyte-mediated cytotoxicity. J. Immunol. 147, 722–728 (1991). · doi:10.4049/jimmunol.147.2.722
  4. Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 25, 9543–9553 (2005). · DOI · Paper page
  5. Kingwell, K. Cancer: live screening of immunotherapy targets. Nat. Rev. Drug Discov. 13, 258 (2014). · DOI
  6. Delgoffe, G. M. PP2A’s restraint of mTOR is critical for T(reg) cell activity. Nat. Immunol. 17, 478–479 (2016). · DOI
  7. Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539–543 (2016). · DOI · Paper page
  8. Janssens, V. & Rebollo, A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr. Mol. Med. 12, 268–287 (2012). · DOI · Paper page
  9. Chung, V. et al. Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase-2A, in patients with relapsed solid tumors. Clin. Cancer Res. 23, 3277–3284 (2016). · DOI · Paper page
  10. Hong, C. S., Ho, W., Zhang, C., Yang, C., Elder, J. B. & Zhuang, Z. LB-100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol. Ther. 16, 821–833 (2015). · DOI · Paper page
  11. Gordon, I. K. et al. Protein phosphatase 2A inhibition with LB100 enhances radiation-induced mitotic catastrophe and tumor growth delay in glioblastoma. Mol. Cancer Ther. 14, 1540–1547 (2015). · DOI
  12. Ho, W. S. et al. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget 7, 12447–12463 (2016). · DOI
  13. Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y. & Levy, R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl Acad. Sci. USA 112, E966–972 (2015). · DOI · Paper page
  14. Ho, W. S. et al. LB-100, a novel protein phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett. 415, 217–226 (2018). · DOI
  15. Melero, I., Rouzaut, A., Motz, G. T. & Coukos, G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 4, 522–526 (2014). · DOI · Paper page
  16. Kroesen, B. J., Mesander, G., ter Haar, J. G., The, T. H. & de Leij, L. Direct visualisation and quantification of cellular cytotoxicity using two colour flourescence. J. Immunol. Methods 156, 47–54 (1992). · doi:10.1016/0022-1759(92)90009-i
  17. Lu, J. et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc. Natl Acad. Sci. USA 106, 11697–11702 (2009). · DOI · Paper page
  18. Chang, K. E. et al. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Mol. Cancer Ther. 14, 90–100 (2015). · DOI
  19. Bai, X. et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1alpha-VEGF mediated angiogenesis. Cancer Lett. 355, 281–287 (2014). · DOI
  20. Bai, X. L. et al. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol. Cancer Ther. 13, 2062–2072 (2014). · DOI
  21. Wei, D. et al. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin. Cancer Res. 19, 4422–4432 (2013). · DOI
  22. Haxhinasto, S., Mathis, D. & Benoist, C. The AKT-mTOR axis regulates de novo differentiation of CD4+ Foxp3+ cells. J. Exp. Med. 205, 565–574 (2008). · DOI · Paper page
  23. Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295–303 (2011). · DOI · Paper page
  24. Sukari, A., Nagasaka, M., Al-Hadidi, A. & Lum, L. G. Cancer immunology and immunotherapy. Anticancer Res. 36, 5593–5606 (2016). · DOI
  25. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015). · DOI · Paper page
  26. Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389–1402 (2013). · DOI · Paper page
  27. Kiely, M. & Kiely, P. A. PP2A: the wolf in sheep’s clothing? Cancers 7, 648–669 (2015). · DOI · Paper page
  28. Zhang, M., Yogesha, S. D., Mayfield, J. E., Gill, G. N. & Zhang, Y. Viewing serine/threonine protein phosphatases through the eyes of drug designers. FEBS J. 280, 4739–4760 (2013). · DOI
  29. Li, Y. M., Mackintosh, C. & Casida, J. E. Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Inhibitor specificity of cantharidin and ATP analogues. Biochem. Pharmacol. 46, 1435–1443 (1993). · DOI
  30. Gehringer, M. M. Microcystin-LR and okadaic acid-induced cellular effects: a dualistic response. FEBS Lett. 557, 1–8 (2004). · DOI
  31. Falconer, I. R. & Humpage, A. R. Preliminary evidence for in vivo tumour initiation by oral administration of extracts of the blue-green alga cylindrospermopsis raciborskii containing the toxin cylindrospermopsin. Environ. Toxicol. 16, 192–195 (2001). · DOI
  32. Rossini, G. P., Sgarbi, N. & Malaguti, C. The toxic responses induced by okadaic acid involve processing of multiple caspase isoforms. Toxicon 39, 763–770 (2001). · DOI
  33. Yatsunami, J., Komori, A., Ohta, T., Suganuma, M., Yuspa, S. H. & Fujiki, H. Hyperphosphorylation of cytokeratins by okadaic acid class tumor promoters in primary human keratinocytes. Cancer Res. 53, 992–996 (1993).

Cited by

See all 93

Metadata

Authors
Ho, W. S., Wang, H., Maggio, D., Kovach, J. S., Zhang, Q., Song, Q., Marincola, F. M., Heiss, J. D., Gilbert, M. R., Lu, R., & Zhuang, Z.
Venue
Nature Communications
Published
2018-05-29
Volume
9
Issue
1
Pages
2126-2126
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2806646910
Cited by
93
References
8
FWCI
3.37
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. https://app.cochat.ai/papers/10.1038/s41467-018-04425-z
The paper
Ho, W. S., Wang, H., Maggio, D., Kovach, J. S., Zhang, Q., Song, Q., Marincola, F. M., Heiss, J. D., Gilbert, M. R., Lu, R., & Zhuang, Z. (2018). Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nature Communications. https://doi.org/10.1038/s41467-018-04425-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.